Top 1% Biotech Crashes, Wiping Out A Run, On A Serious Side Effect

By Investor's Business Daily   |   2 years ago
Top 1% Biotech Crashes, Wiping Out A Run, On A Serious Side Effect

Biotech stock Neurogene (NGNE) plunged after a patient in their Rett syndrome study had a serious side effect. The adverse event is linked to gene therapy side effects but doesn't affect Neurogene's platform. Stock dropped over 40%, erasing recent gains.

Read More

Did you find this insightful?